MASH Therapeutic Development Accelerates with Resmetirom and Semaglutide Approvals, Shifting to Cirrhosis Trials

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, represents a severe form of Metabolic dysfunction-associated steatotic liver disease (MASLD), progressing from simple steatosis to fibrosis, cirrhosis, and hepatocellular carcinoma. Historically, therapeutic options have been limited, leaving a significant unmet medical need for a disease with a global prevalence estimated at 38% between 2016-2019, a nearly 50% increase since 1990-2006. This review addresses the critical gap in effective treatments by examining recent breakthroughs and future directions in MASH drug development.

This review article synthesizes the current landscape of therapeutic development for MASH, analyzing recent accelerated approvals and emerging paradigms in clinical trial design. The authors systematically discuss the evolution of MASH treatment strategies, from histology-based endpoints in non-cirrhotic patients to event-driven trials for advanced cirrhosis. Key areas of focus include the integration of noninvasive biomarkers, the development of hybrid endpoints, and the potential of combination therapies to address disease heterogeneity and associated cardiometabolic risks. The review provides an overview of the strategic shifts in drug development to improve patient outcomes and streamline trial processes.

The review highlights a rapid acceleration in MASH therapeutic development, marked by landmark accelerated approvals for resmetirom and semaglutide based on histological improvements in non-cirrhotic patients. A significant paradigm shift is noted towards event-driven trials specifically targeting cirrhosis, reflecting the advanced stage of the disease and its severe complications. The global prevalence of MASLD is estimated at 38% between 2016-2019, demonstrating a nearly 50% increase compared to 1990-2006, underscoring the urgent need for effective therapies. Emerging strategies emphasize the crucial role of noninvasive biomarkers for patient selection and monitoring, alongside the adoption of hybrid endpoints to enhance trial efficiency. Combination therapies are also gaining prominence, aiming to tackle the multifaceted pathology of MASH by targeting various pathways such as hepatic steatosis, inflammation, and fibrosis. This comprehensive approach seeks to improve overall patient outcomes and mitigate systemic cardiometabolic risks associated with the disease. The authors emphasize that:

The rapid evolution of MASH therapeutics, including accelerated approvals and innovative trial designs, signifies a pivotal moment in addressing this global health challenge.